§ 601.41. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
144 words·~1 min read·
/us/cfr/t21/s§ 601.41A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
FDA may grant marketing approval for a biological product on the basis of adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the biological product further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome.
Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.
Connections4 cite this
Citation graph
cites case law
§ 601.41
Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
Fed. Reg.×4
Cites 0Cited by 4 across 1 source